TCGA-94-8491-01A-11R-2326-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 73
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.470
- MYC_TARGETS_V1+0.360
- OXIDATIVE_PHOSPHORYLATION+0.310
- PI3K_AKT_MTOR_SIGNALING+0.200
- DNA_REPAIR+0.190
- P53_PATHWAY+0.170
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.170
- UNFOLDED_PROTEIN_RESPONSE+0.160
- KRAS_SIGNALING_DN+0.110
- ALLOGRAFT_REJECTION+0.040
Top 10 suppressed
- ANGIOGENESIS-0.420
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- HEDGEHOG_SIGNALING-0.380
- UV_RESPONSE_DN-0.360
- TGF_BETA_SIGNALING-0.320
- CHOLESTEROL_HOMEOSTASIS-0.280
- HYPOXIA-0.280
- KRAS_SIGNALING_UP-0.280
- COAGULATION-0.240
- INTERFERON_ALPHA_RESPONSE-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R176 | — | — | 0.787 |
| 2 | SRR1364893 | GTEX | — | 0.771 |
| 3 | 37b95452-c6ab-48f9-abd4-521b33596657 | — | — | 0.769 |
| 4 | TCGA-MT-A67A-01A-11R-A30B-07 | — | — | 0.765 |
| 5 | 9da01737-be8f-4af5-9f8f-47bb892b6339 | — | — | 0.748 |
| 6 | MNG1279 | — | — | 0.748 |
| 7 | cf2834ac-00ed-4372-be25-042f38241196 | — | — | 0.744 |
| 8 | MNG843 | — | — | 0.734 |
| 9 | SRR6013506 | — | cohortA2 | 0.728 |
| 10 | MV411_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.726 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.470 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.360 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.310 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.190 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.170 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.170 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.160 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.110 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.040 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.020 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.020 | Inavolisib | — uncovered |